DelveInsight’s, “Postoperative Pain Pipeline Insight, 2026” report provides comprehensive insights about 40+ companies and 50+ pipeline drugs in Postoperative Pain pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Get a Free Sample PDF Report to know more about Postoperative Pain Pipeline Therapeutic Assessment @ https://www.delveinsight.com/sample-request/postoperative-pain-pipeline-insight

Key Takeaways from Postoperative Pain Pipeline Report

• In May 2026- Haisco Pharmaceutical Group Co., Ltd. initiated a Phase II Clinical Study to Evaluate the Efficacy and Safety of HSK55718 Injection for Postoperative Pain Treatment in Abdominal Surgery.
• In May 2026- Brazilian Clinical Research Institute conducted a Phase III clinical trial, multicentre, superiority, randomized, open, parallel groups, with active control and use of postoperative oral medication (multiple doses of medication).
• In April 2026- Cali Pharmaceuticals LLC announced a phase 3 study drug during bunionectomy and are followed for pain and opioid use, with the hypothesis that those who receive CPL-01 will have less pain and less opioid use than either control arm.
• In March 2026- Heron Therapeutics conducted a Phase 3, randomized, double-blind, saline placebo- and active-controlled, multicenter study to evaluate the analgesic efficacy and safety of HTX 011 administered via local administration into the surgical site in subjects undergoing bunionectomy.
• In February 2026- Viatris Specialty LLC initiated a MR-107A-02 study is being studied to investigate its efficacy and safety for treatment of acute pain after herniorrhaphy.
• DelveInsight’s Postoperative Pain pipeline report depicts a robust space with 40+ active players working to develop 50+ pipeline therapies for Postoperative Pain treatment.
• The leading Postoperative Pain companies include Ensysce Biosciences, Nevakar, Sustained Therapeutics, Concentric Analgesics, G2GBIO, LipoCure, Bexson Biomedical, Allay Therapeutics and others.
• Promising Postoperative Pain Therapies include INSB-200, BB-106, ATX-201, ST-2427, LC-400, FX 301, NVK-009, HR021618, CA-008, OCS-01, HSK21542, VVZ-149, and others.

Discover groundbreaking developments in Postoperative Pain Therapies! @ Postoperative Pain Ongoing Clinical Trials Assessment

Postoperative Pain Overview

Postoperative pain is a complex physiological and psychological response to surgery, typically resulting from tissue damage, inflammation, and the body’s stress response. Effective management of postoperative pain is crucial for recovery, as uncontrolled pain can hinder healing, increase the risk of complications, delay recovery, and lead to chronic pain if not managed appropriately. The pain differs in quality and location from pain experienced prior to surgery, and is usually associated with iatrogenic neuropathic pain caused by surgical injury to a major peripheral nerve. Acute pain occurs immediately after surgery and lasts for days to weeks due to tissue injury and inflammation. Chronic post-surgical pain (CPSP) persists for over three months, affecting 10-50% of patients depending on surgery type and risk factors. Neuropathic pain results from nerve damage during surgery, causing burning, tingling, or shooting sensations.

Postoperative Pain Emerging Drugs Profile

• PF614: Ensysce Biosciences

PF614 is an oxycodone-based pain medication that has been chemically modified to be inactive until swallowed where it uses one’s own digestive enzymes to activate and release oxycodone to fight pain. Oxycodone has been used for many years to help manage pain severe enough to require an opioid when other pain treatments do not treat pain well enough or you cannot tolerate them. The Ensysce TAAP™ chemical modification delivers pain-relieving medication in a similar manner as OxyContin but with a number of advantages. The pain relief from PF614 should last about 12 hours per dose and you can take it with or without food. Currently, the drug is in the Phase III stage of its development for the treatment of Postoperative Pain as per the company pipeline.

• ATX101: Allay Therapeutics

ATX101 is a novel investigational configuration of an approved, well-characterized, validated intracellular sodium ion channel blocker, bupivacaine, and a biopolymer that has been designed to provide weeks of pain relief following total knee arthroplasty (TKA, or replacement), a common orthopedic surgery. ATX101 has a high density of drug within its small footprint to allow for ultra-sustained analgesia. It is placed in minutes at the end of standard surgery to deliver its analgesic effect over weeks before eventually dissolving into water and carbon dioxide. The simple procedure does not require specialized training and is intended to replace the existing complex mix of analgesic products used for shorter-term pain management in the post-surgical setting. Currently, the drug is in Phase II stage of its clinical trial for the treatment of Postoperative Pain.

• LC-400: LipoCure

LC-400 is an Ultra-Long-Acting Local Anesthetic (ULALA) developed by LipoCure, designed to provide extended post-operative pain relief with a single administration. It consists of a multi-vesicular liposome hydrogel formulation loaded with bupivacaine, enabling a slow and controlled drug release for prolonged analgesic effects while improving safety and efficacy. By maintaining sustained bupivacaine levels at the target site, LC-400 minimizes the need for additional analgesics like NSAIDs or opioids, reducing associated side effects. Phase I clinical studies have shown promising results, and the drug is advancing to Phase II trials.

• GB-6002: G2GBIO

G2GBIO’s GB-6002 is an extended-release injectable formulation utilizing ropivacaine, designed for direct administration at the surgical site. This approach reduces systemic drug exposure compared to conventional administration methods, thereby minimizing side effects while aiming to provide pain relief for more than three days with a single dose. The company has completed a clinical pharmacology study domestically, confirming favorable pharmacokinetic results, safety, and tolerability. Currently, the drug is in Phase I stage of its clinical trial for the treatment of Postoperative Pain.

Uncover critical updates on therapeutic innovations and their potential impact on Postoperative Pain patients @ Postoperative Pain Unmet Needs

Postoperative Pain Companies

Ensysce Biosciences, Nevakar, Sustained Therapeutics, Concentric Analgesics, G2GBIO, LipoCure, Bexson Biomedical, Allay Therapeutics and others.

Postoperative Pain pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Postoperative Pain Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

The Postoperative Pain Pipeline Report Provides Insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Postoperative Pain with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Postoperative Pain Treatment.
• Postoperative Pain Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Postoperative Pain Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Postoperative Pain market

Transform your understanding of the Postoperative Pain Pipeline! @ Postoperative Pain Market Drivers and Barriers, and Future Perspectives

Scope of the Postoperative Pain Pipeline Report

• Coverage- Global
• Postoperative Pain Companies- Ensysce Biosciences, Nevakar, Sustained Therapeutics, Concentric Analgesics, G2GBIO, LipoCure, Bexson Biomedical, Allay Therapeutics and others.
• Postoperative Pain Therapies- INSB-200, BB-106, ATX-201, ST-2427, LC-400, FX 301, NVK-009, HR021618, CA-008, OCS-01, HSK21542, VVZ-149, and others.
• Postoperative Pain Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Postoperative Pain Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Access the Full Postoperative Pain Pipeline Analysis Today! @ Postoperative Pain Drugs and Companies

Table of contents

1. Introduction
2. Executive Summary
3. Postoperative Pain: Overview
4. Pipeline Therapeutics
5. Therapeutics Assessment
6. Postoperative Pain– DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. PF614: Ensysce Biosciences
9. Mid Stage Products (Phase II)
10. ATX101: Allay Therapeutics
11. Early Stage Products (Phase I
12. GB-6002: G2GBIO
13. Preclinical and Discovery Stage Products
14. Inactive Products
15. Postoperative Pain Key Companies
16. Postoperative Pain Key Products
17. Postoperative Pain- Unmet Needs
18. Postoperative Pain- Market Drivers and Barriers
19. Postoperative Pain- Future Perspectives and Conclusion
20. Postoperative Pain Analyst Views
21. Postoperative Pain Key Companies
22. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/postoperative-pain-pipeline-insight